Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells.
Harmonie Perdreau-DahlCinzia ProgidaStefan J BarfeldHanne GuldstenBernd ThiedeMagnus Øverlie ArntzenOddmund BakkeIan G MillsStefan KraussJens Preben MorthPublished in: Communications biology (2020)
Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) was first described as an auto-antigen over-expressed in Sjögren's syndrome and in scleroderma patients. SSSCA1 has been linked to mitosis and centromere association and as a potential marker candidate in diverse solid cancers. Here we characterize SSSCA1 for the first time, to our knowledge, at the molecular, structural and subcellular level. We have determined the crystal structure of a zinc finger fold, a zinc ribbon domain type 2 (ZNRD2), at 2.3 Å resolution. We show that the C-terminal domain serves a dual function as it both behaves as the interaction site to Tankyrase 1 (TNKS1) and as a nuclear export signal. We identify TNKS1 as a direct binding partner of SSSCA1, map the binding site to TNKS1 ankyrin repeat cluster 2 (ARC2) and thus define a new binding sequence. We experimentally verify and map a new nuclear export signal sequence in SSSCA1.
Keyphrases
- systemic sclerosis
- end stage renal disease
- interstitial lung disease
- case report
- healthcare
- chronic kidney disease
- newly diagnosed
- dna binding
- binding protein
- single molecule
- prognostic factors
- hiv testing
- systemic lupus erythematosus
- high density
- patient reported outcomes
- human health
- hiv infected
- men who have sex with men